Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 6 | 2022 | 560 | 1.200 |
Why?
|
| Adenoma | 1 | 2022 | 132 | 0.780 |
Why?
|
| Hyperuricemia | 5 | 2016 | 13 | 0.700 |
Why?
|
| Osteoarthritis, Knee | 5 | 2016 | 26 | 0.690 |
Why?
|
| Dinoprostone | 2 | 2022 | 110 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 331 | 0.280 |
Why?
|
| Magnesium | 2 | 2016 | 110 | 0.280 |
Why?
|
| Uric Acid | 2 | 2016 | 37 | 0.280 |
Why?
|
| Neoplastic Stem Cells | 3 | 2021 | 84 | 0.270 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 180 | 0.270 |
Why?
|
| Cyclooxygenase 2 | 2 | 2022 | 160 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 265 | 0.220 |
Why?
|
| Diet | 2 | 2016 | 513 | 0.220 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2022 | 12 | 0.220 |
Why?
|
| Receptors, CXCR3 | 1 | 2021 | 16 | 0.210 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2021 | 14 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 86 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 91 | 0.200 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 30 | 0.200 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 306 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 222 | 0.200 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 95 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 239 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2021 | 212 | 0.180 |
Why?
|
| Mice | 6 | 2022 | 8472 | 0.180 |
Why?
|
| PPAR delta | 1 | 2019 | 14 | 0.180 |
Why?
|
| Dietary Fats | 1 | 2019 | 103 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 231 | 0.160 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 21 | 0.150 |
Why?
|
| Bupivacaine | 1 | 2016 | 27 | 0.150 |
Why?
|
| Coffee | 1 | 2016 | 18 | 0.140 |
Why?
|
| Soy Milk | 1 | 2016 | 1 | 0.140 |
Why?
|
| Osteophyte | 1 | 2016 | 1 | 0.140 |
Why?
|
| Gout | 1 | 2016 | 9 | 0.140 |
Why?
|
| Mice, Inbred NOD | 4 | 2019 | 138 | 0.140 |
Why?
|
| Thrombospondins | 1 | 2015 | 5 | 0.140 |
Why?
|
| Arthroscopy | 1 | 2016 | 95 | 0.140 |
Why?
|
| Hematocrit | 1 | 2015 | 70 | 0.140 |
Why?
|
| Knee Joint | 1 | 2016 | 115 | 0.140 |
Why?
|
| beta Catenin | 1 | 2015 | 73 | 0.130 |
Why?
|
| Animals | 7 | 2022 | 20877 | 0.130 |
Why?
|
| Celecoxib | 1 | 2015 | 22 | 0.130 |
Why?
|
| China | 4 | 2016 | 138 | 0.130 |
Why?
|
| Osteoarthritis, Hip | 1 | 2015 | 12 | 0.130 |
Why?
|
| Analgesics | 1 | 2016 | 118 | 0.130 |
Why?
|
| Zinc | 1 | 2015 | 73 | 0.130 |
Why?
|
| Cross-Sectional Studies | 6 | 2016 | 2264 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2015 | 46 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2019 | 447 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2016 | 214 | 0.120 |
Why?
|
| Humans | 17 | 2022 | 68525 | 0.120 |
Why?
|
| Odds Ratio | 4 | 2016 | 880 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 334 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 510 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2015 | 331 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 235 | 0.100 |
Why?
|
| Calcium | 1 | 2016 | 929 | 0.100 |
Why?
|
| Prevalence | 4 | 2016 | 1609 | 0.100 |
Why?
|
| Mice, SCID | 3 | 2017 | 238 | 0.100 |
Why?
|
| Radiography | 3 | 2016 | 572 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2019 | 682 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 475 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2013 | 1173 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1046 | 0.080 |
Why?
|
| Risk Factors | 5 | 2016 | 5719 | 0.080 |
Why?
|
| Male | 11 | 2019 | 37281 | 0.080 |
Why?
|
| HCT116 Cells | 2 | 2019 | 63 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2021 | 326 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 304 | 0.070 |
Why?
|
| Female | 9 | 2021 | 38015 | 0.070 |
Why?
|
| Biomarkers | 3 | 2016 | 1593 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2015 | 272 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 2790 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 546 | 0.060 |
Why?
|
| Neoplasms | 1 | 2015 | 1660 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 1172 | 0.060 |
Why?
|
| Middle Aged | 6 | 2016 | 21119 | 0.060 |
Why?
|
| Logistic Models | 2 | 2016 | 1419 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 35 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2021 | 42 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2021 | 37 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 196 | 0.050 |
Why?
|
| Cyclooxygenase 1 | 1 | 2019 | 29 | 0.050 |
Why?
|
| Nanog Homeobox Protein | 1 | 2019 | 6 | 0.040 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2019 | 38 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 498 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2019 | 166 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 81 | 0.040 |
Why?
|
| Thiazoles | 1 | 2019 | 95 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cell Movement | 1 | 2021 | 630 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 852 | 0.040 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 7 | 0.040 |
Why?
|
| Adult | 4 | 2016 | 21375 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 756 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 614 | 0.040 |
Why?
|
| Heterografts | 1 | 2017 | 70 | 0.040 |
Why?
|
| Injections, Intra-Articular | 1 | 2016 | 15 | 0.040 |
Why?
|
| Protective Factors | 1 | 2016 | 24 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2015 | 57 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 211 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2015 | 20 | 0.030 |
Why?
|
| Dosage Forms | 1 | 2015 | 20 | 0.030 |
Why?
|
| Joints | 1 | 2015 | 30 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2015 | 124 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 170 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 319 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 107 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 488 | 0.030 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2013 | 2 | 0.030 |
Why?
|
| Sumoylation | 1 | 2013 | 4 | 0.030 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 22 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 196 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 791 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 132 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2013 | 85 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 282 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2013 | 176 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2013 | 294 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 621 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 532 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1265 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 710 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 434 | 0.030 |
Why?
|
| Wound Healing | 1 | 2013 | 260 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 1582 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1753 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 954 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1849 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 1199 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 2093 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1663 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3256 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 902 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2673 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 3702 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1640 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 2688 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 4843 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 7028 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2015 | 7264 | 0.010 |
Why?
|
| Aged | 1 | 2015 | 14842 | 0.010 |
Why?
|